Astellas Announces Positive Top-Line Results from China ARCHES Trial of Enzalutamide in mHSPC

On March 14, Astellas Pharma, Inc. announced that the Chinese ARCHES study of enzalutamide had reached its primary endpoint. Compared with placebo combined with androgen deprivation therapy (ADT), enzalutamide combined with ADT significantly delayed time to prostate-specific antigen (PSA) progression. In the primary analysis, the safety profile of enzalutamide combined with ADT was generally consistent with the known safety profile of the drug.